CL2017001961A1 - Vacuna bivalente contra el virus de gripe porcina - Google Patents

Vacuna bivalente contra el virus de gripe porcina

Info

Publication number
CL2017001961A1
CL2017001961A1 CL2017001961A CL2017001961A CL2017001961A1 CL 2017001961 A1 CL2017001961 A1 CL 2017001961A1 CL 2017001961 A CL2017001961 A CL 2017001961A CL 2017001961 A CL2017001961 A CL 2017001961A CL 2017001961 A1 CL2017001961 A1 CL 2017001961A1
Authority
CL
Chile
Prior art keywords
virus
subject
swine flu
vaccine against
flu virus
Prior art date
Application number
CL2017001961A
Other languages
English (en)
Inventor
Eric Martin Vaughn
Marc Allan Eichmeyer
Wesley Scott Johnson
Michelle L Walz
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of CL2017001961A1 publication Critical patent/CL2017001961A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN SE REFIERE, ENTRE OTROS, A UNA COMPOSICIÓN INMUNOGÉNICA QUE COMPRENDE: A) UN VIRUS H3 VIVO MODIFICADO DE GRIPE PORCINA, Y B) UN VIRUS H1 VIVO MODIFICADO DE GRIPE PORCINA. POR OTRA PARTE, LA PRESENTE INVENCIÓN SE REFIERE A MÉTODOS PARA INMUNIZAR UN SUJETO QUE COMPRENDE LA ADMINISTRACIÓN A TAL SUJETO DE LA COMPOSICIÓN INMUNOGÉNICA DE LA PRESENTE INVENCIÓN. MÁS AÚN, LA PRESENTE INVENCIÓN SE REFIERE A MÉTODOS DE TRATAMIENTO O PREVENCIÓN DE LOS SIGNOS CLÍNICOS CAUSADOS POR VIRUS DE LA GRIPE PORCINA EN UN SUJETO QUE NO NECESITA, QUE COMPRENDE LA ADMINISTRACIÓN AL SUJETO DE UNA CANTIDAD TERAPÉUTICAMENTE EFECTIVA DE UNA COMPOSICIÓN INMUNOGÉNICA DE ACUERDO CON LA PRESENTE INVENCIÓN.</p>
CL2017001961A 2015-02-26 2017-08-01 Vacuna bivalente contra el virus de gripe porcina CL2017001961A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562121181P 2015-02-26 2015-02-26

Publications (1)

Publication Number Publication Date
CL2017001961A1 true CL2017001961A1 (es) 2018-04-20

Family

ID=55487152

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2017001961A CL2017001961A1 (es) 2015-02-26 2017-08-01 Vacuna bivalente contra el virus de gripe porcina
CL2018002692A CL2018002692A1 (es) 2015-02-26 2018-09-24 Vacuna bivalente contra el virus de gripe porcina.(divisional solicitud 201701961)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2018002692A CL2018002692A1 (es) 2015-02-26 2018-09-24 Vacuna bivalente contra el virus de gripe porcina.(divisional solicitud 201701961)

Country Status (13)

Country Link
US (2) US10029005B2 (es)
EP (1) EP3261664A1 (es)
JP (1) JP6722686B2 (es)
KR (1) KR20170122786A (es)
CN (1) CN107250353B (es)
AU (1) AU2016222962B2 (es)
BR (1) BR112017015789A2 (es)
CL (2) CL2017001961A1 (es)
EA (1) EA201791907A1 (es)
MX (1) MX2017010908A (es)
PH (1) PH12017501370A1 (es)
TW (1) TWI711462B (es)
WO (1) WO2016137929A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0511776B1 (pt) 2004-06-01 2016-11-29 Sinai School Medicine vírus atenuado de influenza de suínos geneticamente engenheirado, formulação imunogênica, formulação farmacêutica, uso da formulação imunogênica, uso do vírus atenuado de influenza de suínos geneticamente engenheirado, uso da formulação farmacêutica e método para produzir uma vacina, uma formulação imunogênica ou uma formulação farmacêutica
KR20170122786A (ko) 2015-02-26 2017-11-06 베링거잉겔하임베트메디카게엠베하 2가 돼지 인플루엔자 바이러스 백신
EP3727444A1 (en) * 2017-12-18 2020-10-28 Intervet International B.V. Swine influenza a virus vaccine
MX2020006327A (es) 2017-12-20 2020-09-17 Boehringer Ingelheim Vetmedica Gmbh Deteccion de vacunas vivas modificadas contra el virus de la gripe porcina.
US11464852B2 (en) * 2018-09-20 2022-10-11 Boehringer Ingelheim Vetmedica Gmbh Modified PEDV spike protein
US12064478B2 (en) * 2018-09-21 2024-08-20 Nutech Ventures Methods of making and using universal centralized influenza vaccine genes
JP7206383B2 (ja) * 2018-10-31 2023-01-17 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー 異種スパイクタンパク質を有する４／９１ ｉｂｖワクチン
JP7350864B2 (ja) * 2018-10-31 2023-09-26 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー 異種スパイクタンパク質を有するｈ５２ ｉｂｖワクチン
MX2023012554A (es) 2018-12-12 2023-11-08 Cambridge Tech Llc Vacuna universal contra la gripe.
US12350328B2 (en) * 2019-02-27 2025-07-08 University Of Rochester Multivalent live-attenuated influenza vaccine for prevention and control of equine influenza virus (EIV) in horses
CN114746113B (zh) * 2019-11-29 2025-11-14 勃林格殷格翰动物保健有限公司 针对副鸡禽杆菌和禽脑脊髓炎病毒和禽痘病毒的三联疫苗
WO2021173965A1 (en) 2020-02-28 2021-09-02 Massachusetts Institute Of Technology Identification of variable influenza residues and uses thereof
US20230248817A1 (en) * 2020-06-19 2023-08-10 Intervet Inc. Swine influenza a virus vaccine comprising a nucleic acid construct comprising first, second and third nucleic acid sequences encoding distinct neuraminidase antigens of the virus
CN113186173B (zh) * 2021-04-15 2023-03-31 上海生物制品研究所有限责任公司 一种基于减毒流感病毒载体的新型冠状病毒肺炎疫苗

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US4071618A (en) 1974-09-03 1978-01-31 Research Foundation For Microbial Diseases Of Osaka University Process for preparing virus disease live vaccines
JPS57136528A (en) 1981-02-09 1982-08-23 Hayashibara Biochem Lab Inc Preparation of viral vaccine
JPS5939831A (ja) 1982-08-27 1984-03-05 Biseibutsu Kagaku Kenkyusho:Kk 豚用インフルエンザウイルス不活化ワクチン
US4693981A (en) 1983-12-20 1987-09-15 Advanced Genetics Research Institute Preparation of inactivated viral vaccines
US5106619A (en) 1983-12-20 1992-04-21 Diamond Scientific Co. Preparation of inactivated viral vaccines
JPS60202827A (ja) 1984-03-28 1985-10-14 Chibaken 弱毒痘そうワクチン株
US5840520A (en) 1989-08-28 1998-11-24 Aviron Recombinant negative strand RNA virus expression systems
US5854037A (en) 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US5786199A (en) 1989-08-28 1998-07-28 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5766601A (en) 1990-08-08 1998-06-16 University Of Massachusetts Medical Center Cross-reactive influenza a immunization
US6162432A (en) 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
ATE161190T1 (de) 1991-10-07 1998-01-15 Biogen Inc Vorbeugungsmethode oder behandlung von, durch antigen-präsentierende zellen hervorgerufene, hautkrankheiten mittels inhibitoren der cd2/lfa-3 wechselwirkung
DE570357T1 (de) 1992-05-14 1994-07-28 Polimun Scientific Immunbiologische Forschungsgesellschaft Mbh, Wien Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren.
US7344722B1 (en) 1993-06-29 2008-03-18 The Regents Of The University Of Michigan Cold-adapted influenza virus
DK0702085T4 (da) 1994-07-18 2010-04-06 Conzelmann Karl Klaus Prof Dr Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus
US6300090B1 (en) 1994-07-29 2001-10-09 The Rockefeller University Methods of use of viral vectors to deliver antigen to dendritic cells
US6146873A (en) 1994-11-10 2000-11-14 Baxter Aktiengesellschaft Production of orthomyxoviruses in monkey kidney cells using protein-free media
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
EP0780475B2 (en) 1995-08-09 2006-07-19 SCHWEIZ. SERUM- &amp; IMPFINSTITUT BERN Process for the production of infectious negative-strand RNA viruses
US5840565A (en) 1995-08-22 1998-11-24 The Regents Of The University Of California Methods for enhancing the production of viral vaccines in PKR-deficient cell culture
US6264957B1 (en) 1995-09-27 2001-07-24 The United States Of America As Represented By The Department Of Health And Human Services Product of infectious respiratory syncytial virus from cloned nucleotide sequences
EP0912724B1 (en) 1996-07-15 2009-12-09 The Government of The United States of America, as represented by The Department of Health and Human Services Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
WO1998013501A2 (en) 1996-09-27 1998-04-02 American Cyanamid Company 3' genomic promoter region and polymerase gene mutations responsible for attenuation in viruses of the order designated mononegavirales
JP2001514508A (ja) 1997-03-05 2001-09-11 ユニバーシティー オブ ワシントン Ｃ型肝炎ウイルスの複製を選択的に抑制する薬剤を同定するための新規なスクリーニング法
US5891705A (en) 1997-04-08 1999-04-06 Pentose Pharmaceuticals, Inc. Method for inactivating a virus
US6884414B1 (en) 1997-04-30 2005-04-26 Mount Sinai School Of Medicine Of New York University Recombinant influenza viruses expressing tumor-associated antigens as antitumor agents
DE69842165D1 (de) 1997-05-23 2011-04-21 Us Of America As Represented By The Secretary Of The Dept Of Health And Human Services Herstellung attenuierter parainfluenza-virus impfstoffe aus klonierten nukleotidsequenzen
DE69837764T2 (de) 1997-07-11 2008-01-31 Yale University, New Haven Rhabdovirus mit gentechnisch veränderter hülle
KR20010030630A (ko) 1997-09-19 2001-04-16 윌리암 에이취 캘넌, 에곤 이 버그 약독화 호흡 신시티아 바이러스
DE69937999T2 (de) 1998-06-12 2009-01-29 Avir Green Hills Biotechnology Research Development Trade Ag Interferon induzierende genetisch veränderte attenuierte viren
SK288544B6 (sk) 1998-06-12 2018-03-05 Mount Sinai School Of Medicine Geneticky skonštruovaný oslabený chimérny vírus chrípky, vakcinačný prostriedok a farmaceutický prostriedok s jeho obsahom a ich použitie
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
AT407958B (de) 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
DE122007000070I1 (de) 1999-07-14 2008-01-31 Sinai School Medicine In Vitro-rekonstitution von segmentierten Negativstrang-Rna-Viren
US6800288B2 (en) 2000-03-02 2004-10-05 Polymun Scientific Immunbiologische Forschung Gmbh Recombinant influenza A viruses
AU2001257001A1 (en) 2000-04-10 2001-10-23 Mount Sinai School Of Medicine Of New York University Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
DE10020505A1 (de) 2000-04-26 2001-10-31 Conzelmann Karl Klaus RSV NS Proteine antagonisieren die Interferon (IFN) Antwort
ATE434035T1 (de) 2000-09-25 2009-07-15 Polymun Scient Immunbio Forsch Lebender influenza impfstoff und verfahren zu seiner herstellung
US20080234175A1 (en) 2002-11-13 2008-09-25 Montelione Gaetano T Process for Designing Inhibitors of Influenza Virus Structural Protein 1
BRPI0511776B1 (pt) * 2004-06-01 2016-11-29 Sinai School Medicine vírus atenuado de influenza de suínos geneticamente engenheirado, formulação imunogênica, formulação farmacêutica, uso da formulação imunogênica, uso do vírus atenuado de influenza de suínos geneticamente engenheirado, uso da formulação farmacêutica e método para produzir uma vacina, uma formulação imunogênica ou uma formulação farmacêutica
EP1855713B1 (en) 2005-02-15 2016-04-27 Mount Sinai School of Medicine Genetically engineered equine influenza virus and uses thereof
US20070116717A1 (en) 2005-08-01 2007-05-24 Shneider Alexander M Influenza vaccine compositions and methods
AT502275B8 (de) 2005-08-08 2007-08-15 Greenhills Biotechnology Res D Immunantwort-induzierende zusammensetzungen
JP5603012B2 (ja) 2005-12-02 2014-10-08 トヘ モウント シナイ スクール オフ メディシネ オフ ニューヨーク ウニベルシトイ 非天然表面タンパク質を提示するキメラウイルス及びその使用
US7507411B2 (en) 2006-06-23 2009-03-24 University Of Saskatchewan Attenuated influenza NS1 variants
US9217157B2 (en) 2009-07-27 2015-12-22 Icahn School Of Medicine At Mount Sinai Recombinant influenza viruses and uses thereof
CN102166352B (zh) * 2011-04-13 2013-01-23 华威特（北京）生物科技有限公司 猪流感二价灭活疫苗的制备方法及其产品
US20130189303A1 (en) 2011-08-02 2013-07-25 Yan Zhou Recombinant swine influenza virus and uses thereof
US9017694B2 (en) * 2011-10-07 2015-04-28 Medimmune, Llc Swine influenza hemagglutinin variants
CN103468647B (zh) * 2013-09-03 2015-04-22 华中农业大学 猪流感h1n1和h3n2亚型的二价灭活疫苗
KR20170122786A (ko) 2015-02-26 2017-11-06 베링거잉겔하임베트메디카게엠베하 2가 돼지 인플루엔자 바이러스 백신

Also Published As

Publication number Publication date
EP3261664A1 (en) 2018-01-03
JP2018512388A (ja) 2018-05-17
MX2017010908A (es) 2017-12-07
US20160250318A1 (en) 2016-09-01
TWI711462B (zh) 2020-12-01
PH12017501370A1 (en) 2017-12-18
KR20170122786A (ko) 2017-11-06
AU2016222962A1 (en) 2017-07-13
US20180289795A1 (en) 2018-10-11
US10029005B2 (en) 2018-07-24
WO2016137929A1 (en) 2016-09-01
CL2018002692A1 (es) 2019-01-18
CN107250353A (zh) 2017-10-13
JP6722686B2 (ja) 2020-07-15
EA201791907A1 (ru) 2018-02-28
CN107250353B (zh) 2021-07-23
BR112017015789A2 (pt) 2018-03-27
US10905756B2 (en) 2021-02-02
TW201701900A (zh) 2017-01-16
AU2016222962B2 (en) 2020-05-21

Similar Documents

Publication Publication Date Title
CL2018002692A1 (es) Vacuna bivalente contra el virus de gripe porcina.(divisional solicitud 201701961)
EP4691484A3 (en) Influenza mrna vaccines
CL2017003151A1 (es) Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas
CL2019003805A1 (es) Composiciones inmunógenas de senecavirus a y métodos de éstas.
CO2019000214A2 (es) Vacuna contra virus de bronquitis infecciosa
MX2016012845A (es) Vacuna contra el virus de la diarrea epidemica porcina.
MX2019005402A (es) Terapias de combinacion del inhibidor de arginasa.
CO6551750A2 (es) Vacuna del virus del dengue inactivado que incluye un adyuvante sin aluminio
CL2018001159A1 (es) Vacuna para adenovirus aviar (divisional de solicitud n° 358-2016)
MX2015016627A (es) Vacuna para la malaria.
MX2020004543A (es) Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan.
MX2016016746A (es) Composiciones de vacuna con adyuvante dual, preparacion y usos.
BR112019006802A2 (pt) compostos e métodos para diagnóstico e tratamento de infecções virais
CU24580B1 (es) Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas
MX2017011655A (es) Compuestos de aza-piridona y usos de estos.
CO2018010874A2 (es) Vacuna de virus de zika atenuado vivo
BR112018075440A2 (pt) composições e métodos para prevenir e tratar a infecção por zika vírus
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
AR101814A1 (es) Partícula de tipo virus flavivirus
MX2017009306A (es) Vacuna contra la fiebre aftosa.
BR112017028212A2 (pt) vacinação concomitante contra dengue e febre amarela
CL2016000300A1 (es) Métodos terapéuticos
MX2016002903A (es) Composiciones inmunogenas de la glicoproteina g de los virus hendra y nipah.
CU20180110A7 (es) Una composición que comprende pic para el tratamiento del cáncer
EA201401352A1 (ru) Вакцина против вируса шмалленберга (sbv), способы ее получения и применения